texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Bedford Research & Clinical Trials

Texas Oncology-Bedford participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Bedford (Expand)

Anal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Biliary Cancer

STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma

A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206) Read Moreabout STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma

Phase: II

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Bladder Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Breast Cancer

Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

Phase: III

Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)

A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) Read Moreabout Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)

Phase: III

Registry study with Breast Cancer Index

Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT) Read Moreabout Registry study with Breast Cancer Index

Phase: IV

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor Read Moreabout Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

Phase: III

Carcinoid

STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma

A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206) Read Moreabout STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma

Phase: II

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Colon Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Endometrial Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Esophageal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Fallopian Tube Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Gall Bladder Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Gastric Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Head and Neck Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Hematologic

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Kidney Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Leukemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase

A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302) Read Moreabout Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Liver Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Lung Cancer

STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

(FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

Phase: III

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

STAR PH3 EGFRm stage2/3b NSCLC

A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216) Read Moreabout Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Lymphomas

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph3 LOXO-305 vs PC of BTK in MCL

A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019) Read Moreabout Ph3 LOXO-305 vs PC of BTK in MCL

Phase: III

Melanoma

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelodysplastic Syndrome

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelomas

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ovarian Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP)

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC (RAMP)

Phase: II

Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

Phase: III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Pancreatic Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Peritoneal Cancer

Ph3 EpiOvarian FallTube PriPeritoneal

(ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7) Read Moreabout Ph3 EpiOvarian FallTube PriPeritoneal

Phase: III

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556) Read Moreabout Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Prostate Cancer

STAR PH3 Abi+/-Capi mHSPC CAPItello-281

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer(mHSPC) Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281

Phase: III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Rectal Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Renal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Skin Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

Phase: II

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Testicular Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Thyroid Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Urothelial Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Uterine Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Vulvar Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II